Pharma BD Deal Intelligence
Sustiva became a real blockbuster, but Coumadin was already melting, imaging was sold off for pennies on the dollar, and BMS wrote off $2.7B almost immediately — a mixed, no-better-than-average outcome.
Full analysis, sources & comparables →BMS positioned the deal as essential to CEO Peter Dolan's plan to double pharma sales 2000-2005, with Sustiva characterized as 'best-in-class' NNRTI and…
BMS closed the $7.8B DuPont Pharmaceuticals acquisition on Oct 1, 2001, gaining $1.5B in annual sales and a virology/cardiovascular pipeline.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Announced 2001-06-07; closed 2001-10-01. BMS acquired DuPont's pharma unit; key assets Sustiva (efavirenz, HIV NNRTI), Coumadin, Cardiolite. Source: SEC 8-K, BMS press release.
Sustiva became a real blockbuster, but Coumadin was already melting, imaging was sold off for pennies on the dollar, and BMS wrote off $2.7B almost immediately — a mixed, no-better-than-average outcome.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / DuPont Pharmaceuticals Company (this deal) | 2001 | $7.8B | 51 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |